[go: up one dir, main page]

BG64475B1 - Ципразидонови соли - Google Patents

Ципразидонови соли

Info

Publication number
BG64475B1
BG64475B1 BG108606A BG10860604A BG64475B1 BG 64475 B1 BG64475 B1 BG 64475B1 BG 108606 A BG108606 A BG 108606A BG 10860604 A BG10860604 A BG 10860604A BG 64475 B1 BG64475 B1 BG 64475B1
Authority
BG
Bulgaria
Prior art keywords
ziprasidone
salts
ziprasidone salts
esylate
neuroleptic
Prior art date
Application number
BG108606A
Other languages
English (en)
Inventor
Kevin Johnson
Yesook Kim
Ravi Shanker
Original Assignee
Pfizer Inc., a corporation organized аnd existing under the laws of the State of Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., a corporation organized аnd existing under the laws of the State of Delaware filed Critical Pfizer Inc., a corporation organized аnd existing under the laws of the State of Delaware
Publication of BG64475B1 publication Critical patent/BG64475B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Hydrogenated Pyridines (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)

Abstract

Изобретението се отнася до ципразидонови соли, по-специално езилатна, мезилатна и тартаратна сол на ципразидона, за получаване на включени комплекси с циклодекстрини за формулиране на фармацевтични състави с невролептично приложение.@
BG108606A 1996-05-07 2004-02-25 Ципразидонови соли BG64475B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07
PCT/IB1997/000321 WO1997041896A2 (en) 1996-05-07 1997-04-01 Inclusion complexes of aryl-heterocyclic salts

Publications (1)

Publication Number Publication Date
BG64475B1 true BG64475B1 (bg) 2005-04-30

Family

ID=21791976

Family Applications (3)

Application Number Title Priority Date Filing Date
BG102894A BG64474B1 (bg) 1996-05-07 1998-11-03 Състави, включващи арил-хетероциклени соли
BG108606A BG64475B2 (bg) 1996-05-07 1998-11-03 Ципразидонови соли
BG108606A BG64475B1 (bg) 1996-05-07 2004-02-25 Ципразидонови соли

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BG102894A BG64474B1 (bg) 1996-05-07 1998-11-03 Състави, включващи арил-хетероциклени соли
BG108606A BG64475B2 (bg) 1996-05-07 1998-11-03 Ципразидонови соли

Country Status (47)

Country Link
US (2) US6232304B1 (bg)
EP (1) EP0900088B1 (bg)
JP (1) JP3579060B2 (bg)
KR (1) KR20000010823A (bg)
CN (1) CN1216923A (bg)
AP (1) AP796A (bg)
AR (2) AR007002A1 (bg)
AT (1) ATE257714T1 (bg)
AU (1) AU713711B2 (bg)
BG (3) BG64474B1 (bg)
BR (1) BR9709213A (bg)
CA (1) CA2251912C (bg)
CO (1) CO4600677A1 (bg)
CZ (1) CZ297847B6 (bg)
DE (1) DE69727218T2 (bg)
DK (1) DK0900088T3 (bg)
DZ (1) DZ2220A1 (bg)
EA (1) EA001731B1 (bg)
EG (1) EG24135A (bg)
ES (1) ES2212809T3 (bg)
GE (1) GEP20074185B (bg)
GT (1) GT199700044A (bg)
HN (1) HN1997000039A (bg)
HR (1) HRP970237B1 (bg)
HU (1) HU222451B1 (bg)
ID (1) ID16866A (bg)
IL (1) IL126546A (bg)
IS (1) IS2524B (bg)
MA (1) MA24172A1 (bg)
ME (1) ME00880B (bg)
MY (1) MY121999A (bg)
NO (1) NO324373B1 (bg)
NZ (1) NZ332220A (bg)
OA (1) OA10907A (bg)
PL (1) PL189324B1 (bg)
PT (1) PT900088E (bg)
RS (1) RS49532B (bg)
SA (1) SA97180024B1 (bg)
SI (1) SI0900088T1 (bg)
SK (1) SK282032B6 (bg)
TN (1) TNSN97075A1 (bg)
TR (1) TR199802231T2 (bg)
TW (1) TW514529B (bg)
UA (1) UA57734C2 (bg)
UY (1) UY24544A1 (bg)
WO (1) WO1997041896A2 (bg)
ZA (1) ZA973874B (bg)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE277641T1 (de) * 1996-05-07 2004-10-15 Pfizer Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP1542668B1 (en) * 2002-08-20 2009-04-15 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
EA200500342A1 (ru) * 2002-09-17 2005-08-25 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Гетероциклические замещённые пиперазины для лечения шизофрении
KR20050055781A (ko) * 2002-10-25 2005-06-13 화이자 프로덕츠 인크. 신규한 데포 주사 제형
PL375603A1 (en) * 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
BR0315866A (pt) * 2002-10-31 2005-09-27 Pfizer Prod Inc Conjugados lìquidos de produtos farmacêuticos sólidos
JP2006506397A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体及び半固体高分子イオン・コンジュゲート
MXPA03009945A (es) 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
US7678799B2 (en) * 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
AU2004296863B2 (en) * 2003-12-08 2008-12-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
CN104059072B (zh) 2006-07-10 2016-06-22 Paion英国有限公司 短效苯并二氮杂*盐及其多晶型
CA2683276A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
US20250049709A1 (en) * 2021-12-11 2025-02-13 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EA001180B1 (ru) 1996-05-07 2000-10-30 Пфайзер Инк. Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
ATE277641T1 (de) 1996-05-07 2004-10-15 Pfizer Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
BG64475B2 (bg) 2005-04-30
ATE257714T1 (de) 2004-01-15
EA001731B1 (ru) 2001-08-27
US6399777B2 (en) 2002-06-04
MA24172A1 (fr) 1997-12-31
HU222451B1 (hu) 2003-07-28
AP9700977A0 (en) 1997-07-31
CN1216923A (zh) 1999-05-19
NZ332220A (en) 2000-03-27
US20010031756A1 (en) 2001-10-18
ID16866A (id) 1997-11-20
JP3579060B2 (ja) 2004-10-20
HRP970237B1 (en) 2002-04-30
ZA973874B (en) 1998-11-06
GEP20074185B (en) 2007-08-10
SK282032B6 (sk) 2001-10-08
BG102894A (bg) 1999-09-30
HUP9902799A3 (en) 2000-12-28
PL329928A1 (en) 1999-04-26
US6232304B1 (en) 2001-05-15
OA10907A (en) 2001-10-26
AU713711B2 (en) 1999-12-09
NO324373B1 (no) 2007-10-01
TR199802231T2 (xx) 1999-02-22
DZ2220A1 (fr) 2002-12-03
SA97180024B1 (ar) 2005-12-24
RS49532B (sr) 2006-12-15
HUP9902799A2 (hu) 1999-12-28
HRP970237A2 (en) 1998-12-31
DE69727218T2 (de) 2004-11-18
MY121999A (en) 2006-03-31
ES2212809T3 (es) 2004-08-01
TNSN97075A1 (fr) 2005-03-15
EP0900088B1 (en) 2004-01-14
IL126546A (en) 2001-01-28
KR20000010823A (ko) 2000-02-25
CA2251912A1 (en) 1997-11-13
EP0900088A2 (en) 1999-03-10
DE69727218D1 (de) 2004-02-19
EA199800910A1 (ru) 1999-04-29
SI0900088T1 (en) 2004-04-30
AR007002A1 (es) 1999-10-13
IS2524B (is) 2009-07-15
CZ297847B6 (cs) 2007-04-11
PL189324B1 (pl) 2005-07-29
UA57734C2 (uk) 2003-07-15
BR9709213A (pt) 1999-08-10
AR045528A2 (es) 2005-11-02
SK150498A3 (en) 2000-01-18
YU17297A (sh) 1999-12-27
AU1937297A (en) 1997-11-26
NO985192L (no) 1998-11-06
CO4600677A1 (es) 1998-05-08
TW514529B (en) 2002-12-21
CA2251912C (en) 2003-06-03
BG64474B1 (bg) 2005-04-30
WO1997041896A2 (en) 1997-11-13
UY24544A1 (es) 2000-09-29
HN1997000039A (es) 1997-06-26
CZ346198A3 (cs) 1999-09-15
AP796A (en) 1999-12-24
JPH11509866A (ja) 1999-08-31
PT900088E (pt) 2004-04-30
ME00880B (me) 2006-12-15
GT199700044A (es) 1998-10-02
NO985192D0 (no) 1998-11-06
WO1997041896A3 (en) 1998-01-08
EG24135A (en) 2008-08-06
IL126546A0 (en) 1999-08-17
IS4880A (is) 1998-10-27
DK0900088T3 (da) 2004-04-19

Similar Documents

Publication Publication Date Title
BG64475B1 (bg) Ципразидонови соли
GB2352395A (en) Paroxetine methanesulfonate
HK1135333A1 (en) Method of using diketopiperazines and composition containing them
MY122391A (en) Piperazine derivatives as 5-ht1b antagonists
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
AU2824600A (en) Cosmetics
TR200200068T2 (tr) Nematisital triflüorobütenler
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
BE2011C037I2 (bg)
SE9704546D0 (sv) Novel compounds
YU13301A (sh) Muskarinski agonisti i antagonisti
SE9802937D0 (sv) Novel compounds
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
MXPA04001773A (es) Derivados de 6,7-dihidroxitetrahidroisquinolinas 3-sustituidas parta uso como agentes antibacterianos.
BG105204A (bg) Соли на пароксетина
AP2000001946A0 (en) Form V1 5,6-Dichloro-2-(isopropylamino)-1-(B-L-Ribofuranosyl)-1H- benzimidazole.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
JO2199B1 (en) Replaced pyrrols
HK1050203A1 (en) Novel fusidic acid derivatives.
RS47804A (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
DE50004023D1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
BG106352A (bg) Стрептограминови производни, тяхното получаване исъстави, които ги съдържат
UA67058A (en) Composition for treating periodontitis